N

Nanjing Vazyme Biotech Co Ltd
SSE:688105

Watchlist Manager
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Watchlist
Price: 23.5 CNY -6.67% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Nanjing Vazyme Biotech Co Ltd?
Write Note

Nanjing Vazyme Biotech Co Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nanjing Vazyme Biotech Co Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
N
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Short-Term Debt
ÂĄ1.1B
CAGR 3-Years
895%
CAGR 5-Years
105%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Short-Term Debt
ÂĄ4.7B
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Short-Term Debt
ÂĄ173.1m
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Short-Term Debt
ÂĄ168.4k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Short-Term Debt
ÂĄ3.4B
CAGR 3-Years
23%
CAGR 5-Years
14%
CAGR 10-Years
46%
Imeik Technology Development Co Ltd
SZSE:300896
Short-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Nanjing Vazyme Biotech Co Ltd
Glance View

Market Cap
9.3B CNY
Industry
Biotechnology

Nanjing Vazyme Biotech Co., Ltd. engages in the research and development, and production of antibody drugs. The company is headquartered in Nanjing, Jiangsu and currently employs 1,409 full-time employees. The company went IPO on 2021-11-15. The firm's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The firm's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.

Intrinsic Value
23.45 CNY
Fairly Valued
Intrinsic Value
Price
N

See Also

What is Nanjing Vazyme Biotech Co Ltd's Short-Term Debt?
Short-Term Debt
1.1B CNY

Based on the financial report for Dec 31, 2023, Nanjing Vazyme Biotech Co Ltd's Short-Term Debt amounts to 1.1B CNY.

What is Nanjing Vazyme Biotech Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 5Y
105%

Over the last year, the Short-Term Debt growth was 280%. The average annual Short-Term Debt growth rates for Nanjing Vazyme Biotech Co Ltd have been 895% over the past three years , 105% over the past five years .

Back to Top